Sanofi has reported a robust financial performance for fiscal year 2025, with net sales rising 9.9% to reach €43.6 billion ($51.9 billion). These results underscore the French pharma giant’s successful efforts to diversify its revenue streams as it prepares for the upcoming patent expiration of its flagship asset, Dupixent.
Key Financial and Portfolio Highlights:
-
Dupixent’s Dominance: Sales for the immunology biologic surged 25.2% to €15.7 billion. Despite nearing its patent cliff, the drug remains a primary growth engine for Sanofi and its partner Regeneron.
-
Success of New Launches: A group of 12 recently launched products—including the myeloma therapy Sarclisa, RSV jab Beyfortus, and hemophilia A treatment Altuviiio—grew by a collective 34%. Notably, Altuviiio reached “blockbuster” status with €1.2 billion in annual sales, a 77.6% increase.
-
Vaccine Market Dynamics: Beyfortus generated €1.8 billion in revenue, driven by strong uptake in Europe and international markets. This growth offset a significant 27.8% decline in U.S. vaccine sales attributed to shifting federal health policies.
Strategic Roadmap and R&D Focus: CEO Paul Hudson reaffirmed Sanofi’s commitment to an AI-driven R&D strategy to navigate the anticipated industry-wide “patent cliff” in the U.S. market.
The company is anticipating several critical Phase III readouts in 2026. This includes data from the venglustat trials for rare lysosomal storage disorders (Fabry and Gaucher Disease Type 3) in the first half of the year, followed by results for Dupixent in new dermatological indications in the second half.
Source: https://www.pharmaceutical-technology.com/news/sanofi-fy2025-sales-results/?cf-view